Entering text into the input field will update the search result below

Merck, GM among BofA's latest Alpha Surprise picks

Feb. 02, 2023 1:12 PM ETSPDR® S&P 500 ETF Trust (SPY)CMS, PPL, SRE, AES, EQT, XLU, RSP, XLE, XLV, XLK, XLY, SCHW, FFIV, GM, BA, JPM, BMY, DHR, EA, SBUX, HAL, TTWO, PGR, LUV, MRK, DLR, FITB, GD, CHRW, NOC, PCAR, NVR, WFC, MDT, COR, CAH, GIS, URI, AMP, MTB, CSGP, RMD, AVB, HBAN, PFG, CTRA, WTW, FTNT, GNRC, GOOGL, EVRG, XLC, SP500, LHXBy: Kim Khan, SA News Editor8 Comments

Merck Fails To Collect Revenue Claimed

Erik S. Lesser

The BofA quantamental Alpha Surprise Portfolio for February saw more deletions than additions and is still tilted toward defensive sectors.

The portfolio's return was +4.6% in January, underperforming the S&P 500 (SP500) (NYSEARCA:

Recommended For You

Comments (8)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

caltiger profile picture
We don't know the details of tye factors that are considered in the weightage and also how long-term are the holdings meant to be, but for me PCAR is a long-term hold and accumulate.an exemplary company/business.
E
what if u just reverse the two lolol
Bright spot profile picture
I think HAL is still going higher from here.
DKnewb profile picture
Considering taking profits on mrk here.
W
@DKnewb Merck is doing well in business but not well enough to justify a 50% run up in one year for a company with such a large market capitalization. My average cost was $74.00 per share. I sold it in two tranches at $110 per share. You can see how people crowded into the drug stocks on recession fears. Now that the fed cycle is coming to an end, the drug stocks are losing the fast money bidders. At $102, it is not overvalued but not a great buy. I would be interested once again at less than $88 per share. If it runs to $110 again sell half. If it penetrates $120 per share you can let the rest go. Best.
K
Do we now have a list of stocks they r long and short?

(just reverse the buys and sells)
b
Not a fan of ALpha Surprise, nor of Merrill Quant leader Savita. Lots of churn and a shortage of results.
T
So much for the mrk surprise
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.